The unusual level of attention around an FDA advisory committee review of the “TIRF REMS” – the drug safety program for transmucosal immediate-release fentanyl formulations – reflects the ongoing political peril for the agency when it comes to issues of prescription drug abuse.
But for most biopharma companies, the more important message may be in watching whether the concerns about the program undo...



